Failure to induce clinical remission at end of study · people with active UC
It is very uncertain whether antibiotics plus probiotics changes failure to induce clinical remission at end of study compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with active UC
It is very uncertain whether antibiotics plus probiotics changes serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
It is very uncertain whether antibiotics plus probiotics changes withdrawals due to adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Failure to maintain clinical remission at end of study · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.73 [0.63, 0.85]
Studies not reported
Moderate
Failure to maintain clinical response · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical response at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.58 [0.48, 0.71]
Studies not reported
Moderate
Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
1 finding from 1 review
RR 0.84 [0.4, 1.78]
Studies not reported
Low
Cardiovascular mortality · people with CKD (including HD and PD)
It is very uncertain whether hypoxia‐inducible factor (HIF) stabilisers changes cardiovascular death Median compared with placebo (very low certainty).
1 finding from 1 review
Fatigue · people with CKD (including HD and PD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Life participation · people with CKD (including HD and PD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nonfatal myocardial infarction Median · people with CKD (including HD and PD)
It is very uncertain whether hypoxia‐inducible factor (HIF) stabilisers changes nonfatal myocardial infarction Median compared with placebo (very low certainty).
1 finding from 1 review
Nonfatal stroke Median · people with CKD (including HD and PD)
1 finding from 1 review
Blood transfusion · people with CKD (including HD and PD)
Hypoxia‐inducible factor (HIF) stabilisers probably leads to lower proportion of patients requiring blood transfusion Median compared with placebo (moderate certainty).
1 finding from 1 review
Proportion reaching target haemoglobin Median · people with CKD (including HD and PD)
Hypoxia‐inducible factor (HIF) stabilisers probably leads to higher proportion reaching target haemoglobin Median compared with placebo (moderate certainty).
1 finding from 1 review
Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for extra treatment · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found